Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
Status:
Unknown status
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This Phase I/II study will investigate the safety and tolerability of intravitreally
administered 0.5mg and 2.0mg Ranibizumab in three monthly doses followed by a 9 month period
of criteria-based, as-needed retreatment and 12 month of drug safety follow up in subjects
with exudative polypoidal choroidal vasculopathy (PCV) for a total of 24 months.